Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Hedges Its Bet On Alzheimer’s With Eisai Tie-Up

This article was originally published in PharmAsia News

Executive Summary

The big biotech and the Japanese pharma are teaming up to develop four Alzheimer’s treatments in a collaboration that will split development costs and share profits.

You may also be interested in...



Eisai/Biogen Remain In BACE Race As Alzheimer's Contenders Dwindle

Multiple competitors have ended development of BACE inhibitors for the treatment of Alzheimer's disease, but Eisai neurology executive Lynn Kramer tells Scrip that the company still sees a path forward for certain amyloid-targeting drugs.

Roche Considers Moving Two Drugs Into Phase III, Drops Early-Stage Alzheimer’s Compound In Strong 3rd Quarter

Roche is moving into Phase III with a Lucentis successor, lampalizumab, in ophthalmology, but has dropped development of a Phase I BACE inhibitor for Alzheimer’s disease, the company announced during a third-quarter earnings update, which highlighted pipeline tweaks amid comparatively strong product sales.

In Alzheimer’s, There’s A Lot Of Room Under The Radar

At the Alzheimer’s Association International Conference in July, a number of companies reported findings alongside headliners Lilly, Merck and AstraZeneca.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1132940

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel